



The subscription period in Alzinova's rights issue starts today

Today, on 30 May 2022, the subscription period begins for Alzinova AB's (publ) ("Alzinova" or the "Company") rights issue of unit consisting of shares and warrants, which was announced on 19 April 2022 (the "Rights Issue"). The subscription period in the Rights Issue runs up to and including 13 June 2022. However, please note that nominees may have a deadline for subscription in the Rights Issue that falls before 13 June 2022.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED KINGDOM, THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, HONG KONG, NEW ZEALAND, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES THAN SUCH MEASURES WHICH FOLLOWS FROM SWEDISH REGULATIONS.

Terms and time plan for the Rights Issue in summary:

- For every share held on the record date 25 May 2022, the holder was allocated one (1) unit right. Four (4) unit rights entail a right to subscribe for one (1) unit. One (1) unit consists of five (5) shares and four (4) warrants of series TO3.
- The subscription price per unit amounts to SEK 10.50 corresponding to SEK 2.10 per share. The warrants are offered free of charge.
- The Rights Issue entails an issue of not more than 4 052 379 units corresponding with 20 261 895 shares and 16 209 516 warrants.
- Upon full subscription in the Rights Issue, the Company will receive approximately SEK 42.5 million before issue costs and upon full exercise of all warrants, the Company will, additionally, receive a maximum approximately SEK 51.1 million before issue costs.
- The Rights Issue is covered to approximately 80 percent through subscription commitments and underwriting commitments.
- Subscription period: 30 May 2022 – 13 June 2022.
- Trading with unit rights: 30 May 2022 – 8 June 2022.
- Estimated day for announcing the outcome: 15 June 2022.

For full information about the Rights Issue, please see the published Prospectus which is found on the Company's website: www.alzinova.com.

Subscription with pre-emption rights

The shareholders or representatives of shareholders who, on the record date of 25 May 2022, were registered in the share register maintained by Euroclear Sweden AB ("Euroclear") and on behalf of the Company, directly registered shareholders, receive a pre-printed issue report with attached payment advice from Euroclear. In the event that a different number of unit rights than those stated in the preprinted issue report are used for subscription, the special application form, which is available on Mangold's website www.mangold.se/aktuella-emissioner, shall be used as a basis for subscription by cash payment.

Shareholders whose holdings of shares in the Company were nominee-registered with a bank or other nominee on the record date do not receive an issue report or a special application form from Euroclear. Subscription and payment must then instead take place in accordance with instructions from the respective trustee.

Subscription without pre-emption rights

Notification of subscription without pre-emption rights by a trustee is made in accordance with instructions from the respective trustee. For subscription through an endowment insurance or an investment savings account, please contact your manager.

Registration for subscription without pre-emption rights in other respects is done by electronic subscription with Bank ID on Mangold's website www.mangold.se/aktuella-emissioner. Alternatively, through sending a registration form to Mangold by e-mail.

For further information on how to subscribe in the Rights Issue and a few summarizing words from CEO Kristina Torfgård, please see the shareholder letter published on www.alzinova.com or www.mangold.se/aktuella-emissioner/.

Advisors

Mangold Fondkommission AB is the financial advisor to Alzinova in connection with the Rights Issue. Frederesen Advokatbyrå AB is the legal advisor to the Company in connection with the Rights Issue.

For more information, please contact:

Kristina Torfgård, CEO

Telephone: +46 70 846 79 75

E-mail: kristina.torfgard@alzinova.com

For questions regarding the Rights Issue, please contact:

Mangold Fondkommission AB

Tel: +46 8 5030 1595

E-mail: emissioner@mangold.se

About Alzinova AB

Alzinova is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting neurotoxic amyloid-beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that target the toxic amyloid-beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Advisor on Nasdaq First North Growth Market is Corpura info@corpura.se +46 (0)768-532 822. For more information about Alzinova, please visit: www.alzinova.com.

Important Information

Release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions according to law and people in those jurisdictions, in which this press release has been announced or distributed, should inform themselves of and follow such legal restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Alzinova in any jurisdiction. Invitation to the persons concerned to participate in the Rights Issue will only take place through the EU growth prospectus which the Company has published in connection with the Rights Issue.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. The information in this press release may not be announced, published or distributed in or into the United Kingdom, the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Switzerland, South Africa, South Korea or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations.

Within the European Economic Area, no offer is made to the public of securities in any country other than Sweden. In other Member States of the European Union, such an offer may only be made in accordance with the exceptions in the Prospectus Regulation (EU) 2017/1129.

This press release contains certain forward-looking information that reflects the Company's present view of future events as well as financial and operational development. Words such as "intend", "assess", "expect", "may", "plan", "believe", "estimate" and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development, and actual outcomes may differ materially from the statements set forth in the forward-looking information.